Starting July 1, 2026, Medicare’s new GLP-1 Bridge may let some Medicare Part D beneficiaries get certain GLP-1 weight-loss medications for $50 a month.

But this is not open to everyone on Medicare. CMS says you need an eligible type of Medicare drug coverage, your doctor has to submit a prior authorization, and you have to meet specific BMI and health-condition rules. CMS also says the Bridge currently covers Foundayo, Wegovy, and Zepbound KwikPen.

If you have been Googling whether Medicare will cover Wegovy or Zepbound for weight loss, this is the program people are talking about.

What Is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a temporary CMS demonstration program that runs from July 1, 2026 through December 31, 2027.

It was created to give eligible Medicare beneficiaries a lower-cost path to certain GLP-1 medications for obesity treatment, even though Medicare Part D still generally excludes drugs when they are used only for weight loss.

CMS says the Bridge is separate from the standard Part D benefit. That matters because the rules, copay structure, and eligibility process are different from a normal Part D prescription claim.

Who Qualifies for the Medicare GLP-1 Bridge?

CMS says you generally need all of these:

  1. Medicare Part D enrollment in an eligible plan type
  2. a prescription for a covered Bridge drug
  3. a provider-submitted prior authorization
  4. clinical eligibility under CMS’s Bridge criteria

The clinical criteria are where most of the confusion will be.

What Clinical Criteria Do You Have to Meet?

CMS breaks eligibility into three main groups.

1. BMI of 30 or higher

You can qualify if your body mass index is 30 or higher.

You can also qualify if your BMI is 27 to 29.9 and you have at least one of these:

  1. dyslipidemia
  2. hypertension
  3. type 2 diabetes that is not currently being treated with medication
  4. cardiovascular disease

3. BMI of 27 to 29.9 plus obstructive sleep apnea symptoms and another condition

CMS also says you may qualify if your BMI is 27 to 29.9, you have obstructive sleep apnea symptoms, and you have at least one of these:

  1. dyslipidemia
  2. hypertension
  3. type 2 diabetes that is not currently being treated with medication
  4. cardiovascular disease

What If You Already Started a GLP-1 and Your BMI Is Lower Now?

CMS says prior authorization can still be approved for people whose current BMI is lower if they met the Bridge criteria when the medication was started.

That is important because many people who have already lost weight on a GLP-1 will not still have the same starting BMI.

If you are already on one of these medications, documentation matters. Your doctor may need the original starting BMI and the related diagnosis that supported treatment.

Which Medicare Plans Are Eligible?

This is not every Medicare situation.

CMS says the Bridge applies to beneficiaries in:

  1. stand-alone Prescription Drug Plans
  2. Medicare Advantage prescription drug plans in coordinated care plan types, including HMOs, HMOPOS plans, local PPOs, and regional PPOs
  3. employer group waiver plans
  4. Special Needs Plans
  5. Medicare-Medicaid Plans
  6. PACE
  7. LI NET

CMS also says beneficiaries in all 50 states, Washington, D.C., and the U.S. territories can qualify if they meet the rules.

Which GLP-1 Medications Are Covered Under the Bridge?

CMS currently lists these Bridge drugs:

  1. Foundayo
  2. Wegovy
  3. Zepbound KwikPen

If you are searching by brand name, that means the main Medicare GLP-1 Bridge conversation right now is about Wegovy, Zepbound, and Foundayo.

This is one place where the details matter. CMS lists Zepbound KwikPen, not just “Zepbound” broadly. If your doctor is prescribing a specific formulation, it is worth confirming that the prescription matches what CMS says the Bridge covers.

What If You Use a GLP-1 for Diabetes, Sleep Apnea, or Another Covered Diagnosis?

This is where people can get tripped up.

CMS says the Bridge is not for people whose drug is already covered under Medicare Part D for another medically accepted indication.

That includes situations such as:

  1. type 2 diabetes treated with GLP-1 therapy
  2. obstructive sleep apnea treated through an already covered indication
  3. metabolic dysfunction-associated steatohepatitis

In those cases, the medication should usually be processed through regular Medicare Part D coverage instead of the Bridge.

If you are not sure how formularies and plan restrictions work, these related guides help:

  1. What Does Medicare Part D Cover?
  2. What Is a Medicare Part D Formulary?
  3. How to Compare Medicare Part D Plans in the Kansas City Area

Does the Bridge Cost $50 for Everyone?

For approved Bridge claims, CMS says the beneficiary copay is $50 for a one-month supply.

But there are a few important limits:

  1. CMS says the Bridge copay does not count toward your Part D deductible or out-of-pocket threshold.
  2. CMS says Extra Help does not apply to Bridge claims.
  3. Because this is outside regular Part D, the cost structure is different from what many beneficiaries expect.

That means a person can have Extra Help for their normal Part D drugs and still pay the Bridge’s separate $50 monthly copay for an eligible GLP-1.

If you need help with regular Part D costs too, read Medicare Part D Extra Help: Who Qualifies and How It Works.

How Do You Apply?

You do not apply directly the way you would for Extra Help.

CMS says your doctor or other prescriber has to submit the prior authorization for you.

CMS also says prior authorization requests will not be accepted or processed before July 1, 2026.

In plain English, the first step is not calling Medicare and asking for a form. The first step is making sure your prescriber understands the program and is ready to document why you qualify.

Questions to Ask Your Doctor About the GLP-1 Bridge

If you are thinking about one of these medications, these are reasonable questions to bring to your appointment:

  1. Based on my starting BMI and diagnoses, do I meet the CMS Bridge criteria?
  2. Am I trying to use this for obesity treatment, or do I already have a condition that should make the medication go through regular Part D instead?
  3. Which of the covered Bridge drugs makes the most sense for me: Foundayo, Wegovy, or Zepbound KwikPen?
  4. If I already started treatment, do you have the records showing my starting BMI and related condition?
  5. Do any of my medical conditions or current medications make one option a better fit or a worse fit?
  6. What side effects should I expect, and what problems should make me call your office?
  7. Do I have any history that needs extra caution, such as pancreatitis, gallbladder problems, kidney problems, severe stomach issues, or a personal or family history of medullary thyroid carcinoma or MEN 2?
  8. If my Medicare plan should cover this through standard Part D instead of the Bridge, which diagnosis and paperwork will you use?

That last question matters more than people think. Some people will focus on the new $50 Bridge and miss the fact that their medication path may be different because of the diagnosis being treated.

Common Mistakes People May Make

These are the mistakes I would expect to see early:

  1. assuming every Medicare beneficiary qualifies
  2. assuming every weight-loss prescription automatically gets the $50 price
  3. not realizing current GLP-1 users may need proof of their starting BMI
  4. confusing Bridge coverage with normal Part D coverage
  5. thinking Extra Help will reduce the Bridge copay
  6. waiting until the pharmacy rejects the claim before asking whether the prior authorization was submitted correctly

What Should You Do Before July 1?

If you think this may apply to you, I would do four things:

  1. confirm what Medicare drug coverage you have right now
  2. make a list of your diagnoses and current medications
  3. ask your doctor whether your use would go through the Bridge or through standard Part D
  4. ask whether your starting BMI and related condition are documented clearly enough for prior authorization

That is the cleanest way to avoid confusion once the program starts on July 1, 2026.

The Practical Next Step

The Medicare GLP-1 Bridge is real, but it is narrower than the headlines make it sound.

If you qualify, it could be one of the more important Medicare affordability changes of 2026. But if your diagnosis, plan type, or documentation is off, you may still hit a denial or find out the claim should have been processed another way.

If you are in the Kansas City area, I can help you sort out whether your drug coverage setup points to the Bridge, standard Part D, or a different Medicare planning issue entirely. That usually starts with the plan type, the diagnosis being treated, and the exact medication your doctor wants to prescribe.

Frequently Asked Questions

What is the Medicare GLP-1 Bridge?

It is a temporary CMS program that begins July 1, 2026 and lets some Medicare Part D beneficiaries get certain GLP-1 weight-loss drugs for a $50 monthly copay.

Who qualifies for the Medicare GLP-1 Bridge?

CMS says you need an eligible type of Medicare drug coverage, a covered Bridge drug, a provider-submitted prior authorization, and clinical eligibility based on BMI and related conditions.

What BMI do you need for the Medicare GLP-1 Bridge?

CMS says you can qualify with a BMI of 30 or higher. You may also qualify with a BMI of 27 to 29.9 if you have certain related conditions, and in some cases obstructive sleep apnea symptoms plus another qualifying condition.

Which GLP-1 drugs are covered by the Medicare GLP-1 Bridge?

CMS currently lists Foundayo, Wegovy, and Zepbound KwikPen.

Does Medicare Extra Help reduce the GLP-1 Bridge copay?

No. CMS says Extra Help does not apply to Bridge claims.

Does the $50 GLP-1 Bridge copay count toward Part D out-of-pocket costs?

No. CMS says Bridge costs do not count toward the Medicare Part D deductible or the Part D out-of-pocket threshold.

Can current GLP-1 users still qualify if they already lost weight?

Possibly. CMS says prior authorization can still be approved if the beneficiary met the eligibility criteria when treatment started, even if the current BMI is lower now.